NASDAQ:SLRX - Salarius Pharmaceuticals Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $5.00
  • Forecasted Upside: 471.82 %
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$0.87
▼ -0.03 (-3.32%)

This chart shows the closing price for SLRX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Salarius Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SLRX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SLRX

Analyst Price Target is $5.00
▲ +471.82% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Salarius Pharmaceuticals in the last 3 months. The average price target is $5.00, with a high forecast of $5.00 and a low forecast of $5.00. The average price target represents a 471.82% upside from the last price of $0.87.

This chart shows the closing price for SLRX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 1 contributing investment analysts is to buy stock in Salarius Pharmaceuticals.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/28/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/27/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/25/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/23/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/23/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/22/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/20/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/20/2021

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/25/2021HC WainwrightInitiated CoverageBuy$5.00High
6/16/2020BenchmarkInitiated CoverageBuy$5.00Medium
4/27/2020LADENBURG THALM/SH SHInitiated CoverageBuyHigh
(Data available from 10/20/2016 forward)

News Sentiment Rating

-0.50 (Sell)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/24/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/23/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/23/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/22/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
7/22/2021
  • 0 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
8/21/2021
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/20/2021
  • 1 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 3 very negative mentions
10/20/2021

Current Sentiment

  • 1 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 3 very negative mentions
Salarius Pharmaceuticals logo
Salarius Pharmaceuticals, Inc. is a clinical-stage oncology company. The firm focuses on the development of Salarius' clinical pipeline, which targets rare, orphan cancers and cancers with a high unmet need. The company was founded in 2014 and is headquartered in Houston, TX.
Read More

Today's Range

Now: $0.87
Low: $0.87
High: $0.93

50 Day Range

MA: $0.99
Low: $0.83
High: $1.15

52 Week Range

Now: $0.87
Low: $0.63
High: $3.50

Volume

563,103 shs

Average Volume

1,856,414 shs

Market Capitalization

$39.15 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.58

Frequently Asked Questions

What sell-side analysts currently cover shares of Salarius Pharmaceuticals?

The following Wall Street analysts have issued reports on Salarius Pharmaceuticals in the last year: HC Wainwright, and Zacks Investment Research.
View the latest analyst ratings for SLRX.

What is the current price target for Salarius Pharmaceuticals?

1 Wall Street analysts have set twelve-month price targets for Salarius Pharmaceuticals in the last year. Their average twelve-month price target is $5.00, suggesting a possible upside of 471.8%. HC Wainwright has the highest price target set, predicting SLRX will reach $5.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $5.00 for Salarius Pharmaceuticals in the next year.
View the latest price targets for SLRX.

What is the current consensus analyst rating for Salarius Pharmaceuticals?

Salarius Pharmaceuticals currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe SLRX will outperform the market and that investors should add to their positions of Salarius Pharmaceuticals.
View the latest ratings for SLRX.

What other companies compete with Salarius Pharmaceuticals?

How do I contact Salarius Pharmaceuticals' investor relations team?

Salarius Pharmaceuticals' physical mailing address is 2450 Holcombe Blvd. Suite X, Houston TX, 77021. The company's listed phone number is (832) 834-6992 and its investor relations email address is [email protected] The official website for Salarius Pharmaceuticals is www.salariuspharma.com.